Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARC PLISKIN

Allopathic & Osteopathic Physicians Urology

NPI
1174569362
CMS profile
482227
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$7,689.47

131 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARC PLISKIN

NPI 1174569362 · CMS profile ID 482227

Allopathic & Osteopathic Physicians / Urology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARC PLISKIN, NPI 1174569362, CMS profile ID 482227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARC PLISKIN, NPI 1174569362, CMS profile ID 482227. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARC PLISKIN, NPI 1174569362, CMS profile ID 482227, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174569362?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

131 matching records · $7,689.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 131 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–131 of 131.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myovant Sciences Inc. $13.4405/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981489 CMS
Myovant Sciences Inc. $2,275.0005/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981493 CMS
Myovant Sciences Inc. $94.5704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981485 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.2504/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789129777 CMS
Myovant Sciences Inc. $12.9304/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981481 CMS
Blue Earth Diagnostics Limited $26.7104/23/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 844629249 CMS
AstraZeneca Pharmaceuticals LP $92.4804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829580971 CMS
Janssen Biotech, Inc. $15.0904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954703 CMS
Mission Pharmacal Company $11.8904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 754274684 CMS
Myovant Sciences Inc. $14.2904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981477 CMS
COLOPLAST CORP $12.9804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844274155 CMS
Clarus Therapeutics Inc. $10.9504/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855018941 CMS
Astellas Pharma US Inc $15.0004/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821496787 CMS
Bayer HealthCare Pharmaceuticals Inc. $5.2804/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789038261 CMS
Myovant Sciences Inc. $23.9303/31/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981471 CMS
Bayer HealthCare Pharmaceuticals Inc. $2.5103/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789125867 CMS
Bayer HealthCare Pharmaceuticals Inc. $10.9903/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789199551 CMS
Bayer HealthCare Pharmaceuticals Inc. $123.7703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789066763 CMS
Janssen Biotech, Inc. $17.6703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954713 CMS
Myovant Sciences Inc. $1,300.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981467 CMS
UROGEN PHARMA, INC. $5.9803/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826686579 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.2303/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789077817 CMS
Bayer HealthCare Pharmaceuticals Inc. $2.1403/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789086847 CMS
BOSTON SCIENTIFIC CORPORATION $21.6103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777649509 CMS
TOLMAR Pharmaceuticals, Inc. $15.4402/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836489403 CMS
Astellas Pharma US Inc $15.1802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821496781 CMS
Astellas Pharma US Inc $17.6202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821496775 CMS
AstraZeneca Pharmaceuticals LP $13.2401/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830088445 CMS
Myovant Sciences Inc. $14.5401/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834981463 CMS
COLOPLAST CORP $10.6601/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844274131 CMS
Astellas Pharma US Inc $10.0801/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821496769 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,833.82 79
PY2020 $4,148.70 74
PY2021 $7,689.47 131
PY2022 $16,620.26 123
PY2023 $57,084.43 70
PY2024 $13,556.85 42
PY2025 $7,295.73 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,330.00 2
PY2025 Principal investigator $3,519,210.09 271
PY2024 Recipient $5,080.00 3
PY2024 Principal investigator $3,563,367.29 325
PY2023 Recipient $990.00 3
PY2023 Principal investigator $2,312,524.64 348
PY2022 Recipient $1,749.00 1
PY2022 Principal investigator $2,820,009.44 141
PY2021 Principal investigator $3,126,903.15 111
PY2020 Principal investigator $3,375,899.80 350
PY2019 Principal investigator $1,945,683.92 262

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

273 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $10,129.43 12/31/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232924970
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926973
Principal investigator 1 Merck Sharp & Dohme LLC $9,857.91 12/31/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927931
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 12/26/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395598
Principal investigator 1 Janssen Research & Development, LLC $22,572.00 12/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395687
Principal investigator 1 Janssen Research & Development, LLC $41,500.00 12/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175395699
Principal investigator 1 MEDIVATION LLC. $1,188.00 12/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811518
Principal investigator 1 MEDIVATION LLC. $1,188.00 12/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811523
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $56.54 12/19/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401697
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $430.67 12/19/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401705
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401689
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401691
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401693
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401699
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401701
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 12/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401707
Principal investigator 1 PFIZER INC. $46,207.89 12/12/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228706751
Principal investigator 1 MEDIVATION LLC. $264.60 12/11/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811448
Principal investigator 1 MEDIVATION LLC. $1,188.00 12/11/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811493
Principal investigator 1 COLOPLAST CORP $3,495.15 12/09/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927246
Principal investigator 1 Janssen Research & Development, LLC $13,847.00 12/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175395643
Principal investigator 1 Janssen Research & Development, LLC $24,198.00 12/01/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395770
Principal investigator 1 Merck Sharp & Dohme LLC $48,688.24 12/01/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926799
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 11/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401632
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 11/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401636
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $430.67 11/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401638
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 11/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401644
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 11/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401646
Principal investigator 1 Janssen Research & Development, LLC $7,592.00 11/24/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257301
Principal investigator 1 Janssen Research & Development, LLC $52,730.00 11/17/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395609
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 11/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401634
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 11/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401649
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,100.00 11/14/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
PROVONE STUDY No dispute reported 06/30/2026 1247892647
Principal investigator 1 Janssen Research & Development, LLC $44,341.00 11/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395603
Principal investigator 1 PFIZER INC. $92,415.77 11/10/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228803915
Principal investigator 1 PFIZER INC. $92,415.77 11/08/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228804060
Principal investigator 1 Janssen Research & Development, LLC $18,758.00 11/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175395637
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 11/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395731
Principal investigator 1 MEDIVATION LLC. $1,188.00 11/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811966
Recipient PFIZER INC. $330.00 11/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803843
Principal investigator 1 PFIZER INC. $869.88 10/29/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228825078
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $430.67 10/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401651
Principal investigator 1 PFIZER INC. $46,207.89 10/10/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228803923
Principal investigator 1 PFIZER INC. $46,207.89 10/09/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228803910
Principal investigator 1 PFIZER INC. $21,499.00 10/08/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228825877
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 10/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395784
Principal investigator 1 Janssen Research & Development, LLC $5,924.00 10/03/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175395766
Principal investigator 1 MEDIVATION LLC. $1,188.00 10/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811442
Principal investigator 1 MEDIVATION LLC. $1,188.00 10/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811453
Principal investigator 1 MEDIVATION LLC. $12,657.48 10/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811956
Principal investigator 1 MEDIVATION LLC. $1,188.00 10/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228811960
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $54.84 09/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401677
Principal investigator 1 Janssen Research & Development, LLC $45,838.00 09/29/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395759
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 09/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401673
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 09/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401683
Principal investigator 1 Janssen Research & Development, LLC $1,075.00 09/19/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256873
Principal investigator 1 Janssen Research & Development, LLC $303.00 09/19/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256945
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 09/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401663
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $63.39 09/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401667
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $63.39 09/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401669
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 09/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401675
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 09/18/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401679
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 09/17/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401665
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 09/17/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401671
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,155.19 09/17/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401681
Principal investigator 1 Janssen Research & Development, LLC $67,716.00 09/15/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395631
Principal investigator 1 COLOPLAST CORP $3,090.15 09/10/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927244
Principal investigator 1 Organon Llc $600.00 09/10/2025 Non-covered Recipient Entity
Tristate Urologic Services PSC Inc
3475-676 No dispute reported 06/30/2026 1173042188
Principal investigator 1 Janssen Research & Development, LLC $2,018.00 09/09/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256673
Principal investigator 1 PFIZER INC. $46,207.89 09/09/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228718475
Principal investigator 1 Janssen Research & Development, LLC $19,409.00 09/08/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395692
Principal investigator 1 Janssen Research & Development, LLC $32,264.00 09/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395660
Principal investigator 1 MEDIVATION LLC. $1,188.00 09/04/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834738
Principal investigator 1 Merck Sharp & Dohme LLC $313.08 08/31/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926975
Principal investigator 1 PFIZER INC. $46,207.89 08/31/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228717391
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401606
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,155.19 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401612
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401630
Principal investigator 1 Janssen Research & Development, LLC $17,632.00 08/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395707
Principal investigator 1 PFIZER INC. $92,415.77 08/21/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228804065
Principal investigator 1 PFIZER INC. $92,415.77 08/20/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228804072
Principal investigator 1 PFIZER INC. $869.88 08/14/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228844144
Principal investigator 1 COLOPLAST CORP $1,545.08 08/13/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927242
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,000.00 08/11/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
PROVONE STUDY No dispute reported 06/30/2026 1247892389
Principal investigator 1 Janssen Research & Development, LLC $16,918.00 08/11/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395626
Principal investigator 1 Dendreon Pharmaceuticals LLC $10,500.00 08/08/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
PROVONE STUDY No dispute reported 06/30/2026 1247892352
Principal investigator 1 MEDIVATION LLC. $1,188.00 08/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834732
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 08/01/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401604
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 08/01/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401614
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 08/01/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401620
Principal investigator 1 Janssen Research & Development, LLC $5,322.00 07/28/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256983
Principal investigator 1 Janssen Research & Development, LLC $52,730.00 07/28/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395711
Principal investigator 1 PFIZER INC. $46,207.89 07/22/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228804029
Principal investigator 1 PFIZER INC. $46,207.89 07/21/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228803849
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 07/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395653
Principal investigator 1 Janssen Research & Development, LLC $3,293.00 07/04/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395725
Principal investigator 1 MEDIVATION LLC. $1,188.00 07/03/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834688
Principal investigator 1 Janssen Research & Development, LLC $3,585.00 06/25/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256810
Principal investigator 1 Janssen Research & Development, LLC $2,800.00 06/24/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257074
Principal investigator 1 Janssen Research & Development, LLC $3,972.00 06/24/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257442
Recipient Dendreon Pharmaceuticals LLC $5,000.00 06/09/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891635
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,000.00 06/09/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
ProvONE No dispute reported 06/30/2026 1247892214
Principal investigator 1 Janssen Research & Development, LLC $66,011.00 06/09/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395717
Principal investigator 1 Janssen Research & Development, LLC $28,231.00 06/09/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395749
Principal investigator 1 PFIZER INC. $46,207.89 06/09/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228823396
Principal investigator 1 PFIZER INC. $46,207.89 06/08/2025 Non-covered Recipient Entity
TriState urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228834517
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 06/06/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401600
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,500.00 06/05/2025 Non-covered Recipient Entity
ADVANCED UROLOGY ASSOCIATES
ProvONE No dispute reported 06/30/2026 1247892188
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848949
Principal investigator 1 MEDIVATION LLC. $1,188.00 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849477
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849522
Principal investigator 1 MEDIVATION LLC. $1,188.00 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849549
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849555
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849601
Principal investigator 1 MEDIVATION LLC. $1,188.00 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849858
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849874
Principal investigator 1 MEDIVATION LLC. $264.60 06/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850235
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401582
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $430.67 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401590
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401596
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401598
Principal investigator 1 Janssen Research & Development, LLC $14,222.00 06/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175395790
Principal investigator 1 PFIZER INC. $1,767.48 05/24/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228856646
Principal investigator 1 PFIZER INC. $92,412.24 05/23/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841563
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401550
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $83.97 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401554
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401558
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401560
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401562
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 05/22/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401564
Principal investigator 1 PFIZER INC. $92,415.78 05/22/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834561
Principal investigator 1 PFIZER INC. $92,412.24 05/22/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841594
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 05/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401548
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 05/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401556
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 05/16/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401566
Principal investigator 1 Janssen Research & Development, LLC $16,632.00 05/12/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395794
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 04/28/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395753
Principal investigator 1 Janssen Research & Development, LLC $39,434.00 04/25/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395684
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401502
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401540
Principal investigator 1 Janssen Research & Development, LLC $7,621.00 04/24/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256991
Principal investigator 1 PFIZER INC. $46,206.12 04/23/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841618
Principal investigator 1 PFIZER INC. $46,207.89 04/22/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834528
Principal investigator 1 PFIZER INC. $46,206.12 04/22/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841588
Principal investigator 1 MEDIVATION LLC. $13,126.33 04/17/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848838
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848831
Principal investigator 1 MEDIVATION LLC. $66.75 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848848
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848962
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848970
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848975
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848986
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228848992
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849064
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849070
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849078
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849085
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849366
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849404
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849412
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849414
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849461
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849470
Principal investigator 1 MEDIVATION LLC. $66.75 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849530
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849539
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849561
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849589
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849596
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849610
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849665
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849671
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849678
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849726
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849742
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849779
Principal investigator 1 MEDIVATION LLC. $66.75 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849785
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849792
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849866
Principal investigator 1 MEDIVATION LLC. $66.75 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849938
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228849948
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850047
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850057
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850067
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850162
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850170
Principal investigator 1 MEDIVATION LLC. $66.75 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850181
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850190
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850230
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850243
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850250
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850258
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850264
Principal investigator 1 MEDIVATION LLC. $29.40 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850322
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850326
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850336
Principal investigator 1 MEDIVATION LLC. $132.00 04/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850413
Principal investigator 1 PFIZER INC. $9,610.92 04/08/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228860956
Principal investigator 1 Janssen Research & Development, LLC $11,798.00 04/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395621
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 04/03/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395737
Principal investigator 1 MEDIVATION LLC. $1,056.00 04/03/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228850150
Principal investigator 1 Janssen Research & Development, LLC $87,820.00 03/27/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395743
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 03/25/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401460
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 03/25/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401510
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401504
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401508
Principal investigator 1 PFIZER INC. $46,207.89 03/24/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228823480
Principal investigator 1 PFIZER INC. $46,207.89 03/23/2025 Non-covered Recipient Entity
TriState urologic Services PSC Inc dba The Urology Group
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228834567
Principal investigator 1 Janssen Research & Development, LLC $60,130.00 03/21/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395677
Principal investigator 1 Janssen Research & Development, LLC $905.00 03/17/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257067
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 03/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401524
Principal investigator 1 Janssen Research & Development, LLC $15,638.00 03/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395666
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 03/07/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395672
Principal investigator 1 MEDIVATION LLC. $235.20 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855503
Principal investigator 1 MEDIVATION LLC. $235.20 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855547
Principal investigator 1 MEDIVATION LLC. $1,056.00 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855559
Principal investigator 1 MEDIVATION LLC. $235.20 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855598
Principal investigator 1 MEDIVATION LLC. $235.20 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855609
Principal investigator 1 MEDIVATION LLC. $235.20 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856439
Principal investigator 1 MEDIVATION LLC. $1,056.00 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856446
Principal investigator 1 MEDIVATION LLC. $534.00 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856489
Principal investigator 1 MEDIVATION LLC. $534.00 03/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856498
Principal investigator 1 Sumitomo Pharma America, Inc. $6,116.20 03/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630192
Principal investigator 1 Sumitomo Pharma America, Inc. $4,119.00 03/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630196
Principal investigator 1 Sumitomo Pharma America, Inc. $4,500.00 03/05/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630292
Principal investigator 1 PFIZER INC. $92,412.24 03/04/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841581
Principal investigator 1 PFIZER INC. $92,415.78 03/03/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834522
Principal investigator 1 PFIZER INC. $92,412.24 03/03/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841606
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 02/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401506
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 02/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401450
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 02/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401544
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,420.00 02/26/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
PROVONE STUDY No dispute reported 06/30/2026 1247891789
Principal investigator 1 Dendreon Pharmaceuticals LLC $10,500.00 02/26/2025 Non-covered Recipient Entity
THE UROLOGY GROUP
PROVONE STUDY No dispute reported 06/30/2026 1247891793
Principal investigator 1 Janssen Research & Development, LLC $8,721.00 02/21/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256827
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $83.38 02/20/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401452
Principal investigator 1 COLOPLAST CORP $1,747.57 02/13/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927240
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 02/12/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401462
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 02/12/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401478
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $71.98 02/12/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401532
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 02/12/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401534
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 02/10/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401480
Principal investigator 1 Janssen Research & Development, LLC $24,460.00 02/10/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395647
Principal investigator 1 Eli Lilly and Company $28,002.00 02/06/2025 Non-covered Recipient Entity
TRI STATE UROLOGIC SERVICES PSC INC
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187893764
Principal investigator 1 MEDIVATION LLC. $1,056.00 02/06/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855538
Principal investigator 1 Janssen Research & Development, LLC $4,394.00 02/03/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175395615
Principal investigator 1 PFIZER INC. $46,206.12 02/03/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841557
Principal investigator 1 PFIZER INC. $46,207.89 02/01/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228834572
Principal investigator 1 PFIZER INC. $46,206.12 02/01/2025 Non-covered Recipient Entity
The Urology Group
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228841611
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 01/31/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401538
Principal investigator 1 AstraZeneca Pharmaceuticals LP $232,664.36 01/29/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185548398
Principal investigator 1 AstraZeneca Pharmaceuticals LP $174,305.09 01/29/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185548400
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401488
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401522
Principal investigator 1 Sumitomo Pharma America, Inc. $2,212.00 01/29/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176625047
Principal investigator 1 Sumitomo Pharma America, Inc. $2,424.00 01/29/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA THE UROLOGY
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176625074
Principal investigator 1 Janssen Research & Development, LLC $1,810.00 01/28/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257702
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $430.67 01/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401530
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,020.81 01/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401536
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 01/21/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257032
Principal investigator 1 Janssen Research & Development, LLC $400.00 01/21/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257327
Principal investigator 1 Janssen Research & Development, LLC $53,102.00 01/20/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC DBA TUG RESEARCH
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175395776
Principal investigator 1 COLOPLAST CORP $2,000.00 01/17/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927238
Principal investigator 1 Janssen Research & Development, LLC $6,248.00 01/17/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175256898
Principal investigator 1 Janssen Research & Development, LLC $5,574.00 01/17/2025 Non-covered Recipient Entity
Tristate Urologic Svcs Psc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175257385
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 01/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401464
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 01/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401466
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $130.00 01/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401476
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $425.00 01/13/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401512
Principal investigator 1 COLOPLAST CORP $1,747.57 01/09/2025 Non-covered Recipient Entity
The Urology Group
INTIBIA No dispute reported 06/30/2026 1226927236
Principal investigator 1 Merck Sharp & Dohme LLC $10,609.75 01/08/2025 Non-covered Recipient Entity
TriState Urologic Services PSC Inc. dba The Urology Group
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232924968
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $58.26 01/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401500
Principal investigator 1 MEDIVATION LLC. $235.20 01/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228855590
Principal investigator 1 MEDIVATION LLC. $235.20 01/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856351
Principal investigator 1 MEDIVATION LLC. $235.20 01/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856429
Principal investigator 1 MEDIVATION LLC. $1,056.00 01/02/2025 Non-covered Recipient Entity
TRISTATE UROLOGIC SERVICES PSC INC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228856480